.

Parte 5 | Gabriel Lamothe | Seminário Internacional de Ciências Farmacêuticas | Método CRISPR VI

TEXTO DO CANAL BRASIL SEM ALERGIA NO YOUTUBE

O texto pode conter erros na transcrição uma vez que são geradas automaticamente pelo YouTube. Não deixe de assistir o vídeo em nosso canal.

 

0:28 welcome thank you for having me uh let's see if 0:34 we can get it started hi my name is gabriel lamot and today 0:41 i'll be discussing the detection of cyrus kobe yeah that's much better is the sound 0:47 better now b2 using crispr technology oh perfect namely the test that we've been developing in dr tremblay's laboratory 0:55 studies have confirmed that many individuals infected with the sars kobe 2 virus are asymptomatic carriers of the virus 1:02 this is problematic in that the pandemic might be growing without adequate supervision simply focusing the testing on 1:08 individuals with symptoms as opposed to entire populations is not enough 1:14 to better contain the virus until a large scale distribution of an effective vaccine is underway large scale and 1:20 continuous testing is mandatory the current diagnostic pipeline for 1:26 detecting sars cov2 is a three-step process the first step is to obtain nasopharyngeal swabs from 1:32 patients the next step is to isolate the total rna from said samples and provide the rna required for this 1:40 third step which is to use real-time quantitative vcr machines the rna is first reverse transcribed 1:46 into dna and then amplified a dye is added to the amplification reaction to signal the presence of dna 1:52 strands after a certain number of amplification cycles a positive result will give 1:57 a strong enough signal that the machine flags it as containing the original virus now this process is problematic for a 2:04 few reasons the first is that real-time pcr machines are extremely expensive 2:10 most can range from 15 000 us dollars to well over 90 000 us dollars 2:16 given that it's a fairly specialized piece of equipment and that not all molecular biology laboratories need one 2:22 some get along just fine with a regular pcr machine which costs a much more reasonable 5000 us dollars 2:28 as such widespread testing for the coronifiers using these machines isn't ideal 2:33 acquiring the large number of machines required for widespread testing is a feat in and of itself 2:39 and is likely one of the contributing factors for the sometimes long wait times for results 2:45 many reports have stated that it can take 3 to 24 hours or more to obtain results in a clinical 2:51 diagnostic laboratory over here in canada ontario reports wait times of up to four days to get results 2:58 high-density metropolitan areas like new york are also subject to long lines for testing and then a time to 3:05 results of about seven days for some clinics in that city the creation of new types of detection tests 3:12 is therefore an important step in curbing the spread of this virus an ideal test needs to follow the world 3:19 health organization's criteria for assured that is the test needs to be affordable 3:25 for as many people at risk of infection as possible tests that require extremely expensive reagents or machinery 3:31 are not ideal the test must also be specific to avoid false negatives that way anyone 3:37 who could potentially spread the virus can be identified and put into quarantine the test must be sensitive 3:43 so that few people who don't have the virus are mislabeled as having it and treated improperly 3:48 the test must also be user friendly that is it must be simple to perform and it must be rapid and robust that is 3:55 it must give a time to results that is quick enough to make the most use from the results situations where it can take up to seven 4:02 days to obtain results are clearly far from ideal as by the time the patient receives 4:07 the information they might have infected many others the test must be equipment free as much 4:13 as possible tests that require too many rare and expensive machines aren't ideal for many 4:18 countries finally the test must be deliverable to those who need it 4:24 the discovery of cast 13 or c2 c2 was revolutionary in the field of molecular detection 4:31 this class 2 type 6 crispr effector is similar to the protein cast 9 off of 4:36 which base ending and prime ending were designed this protein is also a member of the crispr family 4:43 unlike cas9 however cast 13 can be programmed to target rnas as opposed to dnas 4:49 by binding to its crispr rna cas13 is primed to target extremely specific rna sequences after locating a target 4:57 sequence the cast 13 protein is activated this causes the protein to begin to cleave 5:03 everything its surroundings in an event called collateral cleavage it cleaves its original target 5:08 and then moves on to start cleaving all surrounding rnas researchers realized that this 5:14 collateral cleavage could be used to turn the protein into a switch for a detection test once 5:19 the target molecule is present the switch is flipped the cast cas13 activated and all surrounding rnas are degraded by 5:27 tagging certain rnas in the solution with a fluorescent molecule and a quencher 5:32 it would therefore become possible to resolve a signal researchers therefore started to develop 5:38 a detection test based on this protein for viruses bacteria and human diseases such as cancer 5:45 however they soon noted that there were certain limitations to the protein and that is limited detection was far from sensitive 5:51 enough for their needs recently certain tests have been designed using only cast 13 5:57 however these tests are less sensitive and tend to use a different cast 13 protein 6:03 researchers at the broad institute decided to supplement the protein with a few others that would amplify the 6:08 target rna to this end dr zhang and his team created a new test called specific high sensitivity 6:16 enzymatic reporter unlocking or sherlock for short this test is based 6:21 on the reverse transcription of target rna into dna afterwards the dna is amplified at a 6:27 constant temperature by using a process called recombinase polymerase amplification 6:32 this technique amplifies a small amount of dna at a constant temperature unlike the more commonly used bcr 6:40 the incorporation of this step also means that the ensuing detection test can target dna since the rpa reaction 6:47 simply amplifies a determined section of dna using two primers the initial genetic sequence can either 6:53 be rna or dna so long as reverse transcriptase enzymes are present for rna 7:00 the amplified sequences are then transcribed using a t7 rna polymerase to create vast quantities of the target 7:07 rna this then allows the cas13 to have a far larger pool of target molecules 7:12 which can activate the enzyme once the enzyme is active it does what we discussed before 7:18 and starts to cleave all surrounding rnas including reporter rnas which give off the easily detectable signal 7:24 which makes the test work in their initial version of the sherlock test two different reporter 7:31 molecules were used the first used a fluorescent molecule as well as a quencher 7:37 and it was able to produce a lot of fluorescence after cleavage of the rna the other 7:44 was designed to interact with a few antibodies and when it was cleaved it appeared as a distinct 7:50 second band on a strip that was quite similar to a pregnancy test 7:55 while this test was good in many ways it had certain drawbacks at the beginning of the pandemic we attempted to replicate it and 8:01 immediately had a few issues the biggest issue by far was that some of the materials required for the test 8:07 to work were only available in extremely limited supply the kits required to perform rpa 8:12 reactions for example took approximately two months to arrive and even then we only received enough 8:18 materials to perform 200 tests this clearly wasn't going to be enough to produce sufficient tests in the 8:24 future additionally the reporter that used a pregnancy style strip was remarkable and seemed to be very 8:31 useful however since it was too difficult to acquire insufficient quantities 8:36 we decided not to use it and to instead focus our efforts on using the fluorescent style reporter rna since the original version 8:44 of the test could not be used by us in the way that it was intended we decided to redesign it 8:51 in redesigning the test we had several options and routes that we could take we knew that we wanted to keep on using 8:57 cast 13 because we had a large supply of this enzyme due to an ongoing collaboration with dr 9:02 alain ghani's lab we also knew that we wanted at all costs to maintain the isothermal nature of 9:08 this test one of the biggest advantages to sherlock was that it didn't require large amounts of expensive equipment 9:14 simply by using a heating block or something of the sort it was possible to get a visual readout 9:20 we therefore decided to employ loop-mediated isothermal amplification or lamp for short this amplification 9:27 strategy was fairly well documented and easy enough to perform based on the use of six primers this 9:33 technique could rapidly amplify large amounts of target dna unlike both rpa and pcr however 9:39 lamp doesn't create identical amplicons of a discrete size instead the six primers can interact to 9:46 create far larger molecules of a repeating sequence initially it was a little difficult to 9:52 incorporate this isothermal amplification strategy into our test as you might remember the step following 9:58 rpa in the original sherlock test was one that produced lots and lots of target rna 10:03 this production of target rna was only possible because the rpa step added a tag that let the t7 rna 10:10 polymerase bind to the dna and begin transcribing it however no one had seemingly ever done 10:16 that with lamp and since this new technique used six primers two of which looped back on themselves to create 10:22 weird dumbbell like structure structures it was difficult to figure out exactly where to incorporate this tag 10:29 after a while we decided to include the tag right in the middle of one of our looping primers this has consistently 10:35 given us very strong results we were therefore able to retrofit the original sherlock 10:41 test with a new amplification strategy all the while still benefiting from cast 13's specificity and signaling 10:48 the new test is therefore using rt lamp as opposed to rt rpa of course 10:54 should we become interested in targeting dna in the future for either certain types of viruses or 11:00 certain bacteria this test would be readily applicable to that as well we also decided to use a fluorescent 11:07 reporter rna instead of the pregnancy style one that we spoke about previously because it seemed to be the most readily 11:13 available material since it doesn't take any particularly advanced machinery to make it work 11:18 we were happy to choose this one 11:24 now that you know how the test works from a theoretical standpoint let's discuss it from a more practical point of view for now 11:31 the test requires that we start with rna that was extracted from a virus using a commercially available kit one 11:37 microliter of this solution is transferred over to the tube containing the rt lamp reaction 11:42 ideally in the future we would like to modify the test so that it becomes possible to directly add a patient's saliva 11:48 to it and continue on from there that would noticeably cut down on the labor required to obtain each reading 11:54 cut down on the overall cost and make it much faster for the results to come in 11:59 after transferring one microliter of the rna extract to the first tube the tube must then be incubated at 65 12:05 degrees celsius for 30 minutes after that one microliter is transferred from the first tube 12:11 into the second which contains the t7 and cast 13 solution after tapping the tube a few times to 12:18 mix it and microcentrifuge it down for a few seconds all you need to do is incubate that tube at 37 degrees celsius 12:25 for 30 minutes at that point all of the reactions are done and that the results are ready to be 12:31 read by exposing the tubes to a wavelength of approximately 490 nanometers 12:36 it's possible to easily detect which samples contain cyrus cov2 those ones will fluoresce a bright green 12:43 those that didn't contain any of the viral specimens of interest will be completely colorless and indistinguishable from a tube filled 12:50 with a little water i'll show you that later now it's worth noting that the dna and rna sequences 12:57 that we have used in this first version of our test were all previously published by different groups 13:03 as such we do not believe that they will result in a positive signal when in the presence of a relevant rna 13:10 this is particularly important because your saliva is full of rna the extraction process for the virus 13:16 does indeed indeed result in viral rnas being captured but there tends to be a whole lot more 13:22 human and bacterial rnas too in addition other coronaviruses that are 13:27 much less dangerous are fairly common in the human population if our tests gave positive signals every time someone came in 13:34 with a common cold then it wouldn't be very effective as such we have based ourselves on 13:39 previously described templates to try and avoid this as much as possible 13:45 in designing this test we tried to make sure that it wasn't overly reliant on complicated machines 13:50 we wanted the entire test to be easy to perform using only a few common laboratory apparatuses 13:56 as a result with this current iteration of the test all we need is one machine that can heat 14:02 pcr-style tubes to 65 degrees celsius and one that can heat 14:07 the pcr tubes to 37 degrees celsius we also need two either p2 or p10 14:14 pipettes for reasons we'll get into later along with their associated peptide tips 14:20 a small microcentrifuge capable of taking pcr tubes is also required just to make sure that the reaction 14:26 mixtures don't touch the top of the tube when you're opening them and potentially contaminating 14:31 all of the surrounding tubes finally a machine capable of giving off ultraviolet wavelengths is necessary 14:38 in this picture you'll see the machine i've been using it's most commonly used to visualize gels in a molecular biology 14:44 lab but it does a really good job of visualizing our positive samples in our test for the two incubation 14:52 periods several different options are available i've been using an old thermocycler today 14:57 as i find it does a really good job of evenly heating my tubes it's worth noting here that this means 15:03 that even old and run-down thermocyclers that no longer do a very good job of cycling between temperatures 15:09 can be readily used in this test unlike the current rtq pcr gold standard that requires 15:16 specialized real-time thermocyclers here any old machine can be used 15:22 it's also possible to use other common laboratory apparatuses such as block heaters that have an 15:27 adapter for pcr tubes please note that in this picture the block heater has an adapter for 1.5 15:34 millimeter microcentrifuge tubes so the true adapter will look a little different 15:39 i've also used incubators to great success even bacterial incubators that operate at a steady 37 degrees 15:46 celsius can perfectly suit the needs of this test so long as the tubes are readily exposed 15:51 to the ambient temperature then positive signals should have no difficulty in resolving 15:56 please note however that when using incubators it's better to have the tubes exposed to the air 16:02 that way they don't waste time as their rack slowly begins to heat up 16:07 water baths are one final option that you can choose personally i tend to avoid this option 16:13 because i find the risk for cross-contamination between samples to be much greater and therefore unideal 16:19 however i have tried to perform rt lamp reactions with this system and so long as you're 16:24 careful it's very possible to do it 16:30 once the reactions have been completed it's possible to use various different machines to visualize the tubes depending on the 16:36 materials your laboratory has personally my machine of choice is a gel uv emitter 16:42 these machines which are more commonly used to visualize agarose gels do a very good job of safely showing 16:48 which tubes are fluorescent and which aren't black lights can also be used 16:53 for this test however i have found them to be slightly less desirable since the reporter rna best absorbs 16:59 wavelengths of 490 nanometers i found that black lights which produce wavelengths of 390 nanometers 17:06 to be less favorable for this test for them to work it's better to visualize the tubes in a dark room 17:13 in both cases the machine should really be placed in a darker room away from excessive light a little 17:19 background light seems to have less of an effect in the case of the gel uv light however 17:25 this picture seen on the left was taken using a generic iphone when the tubes were placed on the gel uv 17:31 light the lights in the room were only partially turned off resulting in lots of ambient lighting 17:37 even if there were no lights directly pointed at the machine given the strong and even radiation that the tubes 17:44 received on this machine it's easy to determine which samples were positive and which were negative 17:50 in the case of the black light on the right it's clear which samples are positive and which are negative 17:55 of course however the fluorescence is not even and it's a little bit harder to detect 18:01 by the naked eye in this case the camera on the iphone took a very good picture 18:06 and made it easier to visualize the tubes overall now there are several important 18:11 considerations to be had when using this test for it to work properly and not give either false positives or false 18:17 negatives it's important to first designate proper working stations for each section of the test it's also 18:24 necessary to follow the predetermined reaction times without varying otherwise the results might start to 18:30 differ slightly finally those handling the test must be careful not to contaminate any of the 18:36 tubes with rnases the first consideration to separate 18:41 working areas is extremely important because lamb is excessively sensitive this technique is known to produce lots 18:48 and lots of concentrated target dna we as well as others have noted that 18:54 when we open tubes that completed the lamp amplification in the same area that we originally used 18:59 to set up the reaction it's possible to contaminate the working area with aerosols containing the 19:04 product if you continue to set up the lamp reactions in those areas afterwards then you run the risk of 19:11 contaminating your new tubes with amplicons from the previous reactions by touching your desk or 19:16 various other contaminated surfaces with your gloves you run the risk of artificially seeding your reaction 19:22 mixtures that contain patient rna with no sarisco v2 and therefore producing positive results 19:29 when there really shouldn't have been any by separating the areas in which you set up the lamp reactions 19:34 and those in which you use the amplified sequences you run less of a risk for this to happen it's 19:40 also necessary to have designated lab coats pipettes and other such materials for each working station 19:47 if those in workstation 2 become contaminated you don't want that coming back into workstation 1. 19:53 please note that this is much less stringent when bringing materials from workstation 1 to workstation 2. 19:59 since it's the rt lamp reaction that runs the greatest risk of contamination bring material for example gloves 20:06 from that station to the next should not be a problem provided that the gloves are still 20:12 relatively clean please note that this situation of contamination via aerosol 20:18 is of much less importance during the second stage of the test as we discussed previously the cast 13 20:24 protein we are using requires a relatively large amount of rna to be functional 20:30 at the present time we are not concerned in the least then aerosol contamination from lamp 20:35 might produce false positives of our cast 13 reactions as we have yet to see a single situation 20:41 where this has happened the second consideration of note is that 20:47 the reaction time must be followed a small discrepancy can be tolerated that is one minute more or less doesn't 20:54 really seem to have a large impact on the test however more than that can start to become problematic 21:01 in the case of the rt lamp reaction external teams as well as us have seen that by doubling the reaction 21:07 time for the lamp false positives can arise as you can see here in both pictures 21:13 a successful lamp reaction can also be visualized on an agarose gel the successful reactions are 21:19 characterized by the presence of several large bands of varying sizes however when the lamp 21:25 reactions go on for too long it's possible to begin amplifying samples with nothing in them 21:30 for example on the left you'll see a gel that was taken from an article in which at 30 minutes the wells 21:37 containing reactions with 10 copies of the target are viral rna and no copies of the 21:42 target viral rna had no bands in the case of the gel on the right a gel that i made three of the wells 21:50 contained reactions that had no target rna to speak of only the n fragment well contained 21:56 target rna at 30 minutes these negative controls did not demonstrate any amplification 22:02 as we expected however at 60 minutes both the published gel and mine started 22:08 to give amplified products in their case the ten and zero copies both started to be amplified 22:15 and in my case one of my negative samples started to get amplified i've performed 22:22 several experiments so far with 30 minute incubation times and so far have never gotten false positives that's 22:29 not to say that it's entirely impossible simply that it's very very unlikely as a 22:35 side note this is a good time to mention that changing gloves frequently when performing the first reaction 22:41 is a good way to avoid these kind of unlikely false positives after prolonged use gloves might become 22:47 contaminated with small amounts of viral rna and that could potentially lead to false positives even if we're only incubating 22:54 at 30 minutes the final consideration to look out for 22:59 is the presence of rnases for those of you who might not be familiar rnases are enzymes that cleave 23:05 all rnas they come across both steps for this test are sensitive to rnases 23:11 the initial arty lamp begins its amplification off of rna so the presence of rnases could be very 23:17 detrimental and therefore lead to false negatives the second step of the test the t7 and cast 13 step uses 23:25 an rna reporter to signal positive tubes if while you're using the tests you start to introduce rnases 23:31 then you run the risk of getting false positives rnases are extremely difficult to remove 23:37 once they're introduced into a system so the best means of protecting your test is by using prevention 23:43 since your hands produce lots of rnases it's mandatory to use gloves at all times when working with the test 23:49 in doing so you will prevent your body's natural rnases from degrading the initial star's cov2 23:54 rna and protect the fluorescent reporter at the end gloves must also be changed whenever 24:00 they come into contact with skin hair or other frequently manipulated objects 24:06 such as doorknobs and personal devices the use of rnas and dnase free 24:12 filtered pipettes is also important for this test by using these kinds of specialized tips 24:19 you can make sure that any possible contaminations you might have in your pipettes doesn't have a chance 24:24 to contaminate your test in areas where the risk for rnas contamination is fairly high 24:30 it might be worthwhile to treat all surfaces or tools with an rnas removal solution these 24:36 kinds of solutions can degrade rnases that might otherwise stick to your gloves and contaminate your samples 24:42 please note i haven't had to use the solution very often so long as you maintain a clean 24:48 working schedule you should be fine the second component for the test 24:54 the one containing t7 and cast 13 is also designed to be able to tolerate a 24:59 certain level of contaminating rnases there is an rnas inhibitor added to the reaction mixture 25:06 to prevent the degradation of the reporter in case the original sars kobe 2 rna 25:11 wasn't completely clean or in case contaminations occurred while you were preparing the tests 25:18 that said the presence of excessive rnases can still fully activate the test seen 25:24 here on the right one microliter of very concentrated rnase a is capable of causing the test tube to 25:30 become fluorescent it's therefore important to take the 25:40 required 25:54 cabrillo 26:02 test that can be widely distributed while also meeting this limit of detection is fully functional for curbing the 26:10 spread of this pandemic while rt-qpcr is much more sensitive 26:15 than this its improved limited detection might not necessarily be that beneficial 26:20 since this technique can pick up rnas freed by infected and dead cells after the infection has 26:26 run its course this form of screening can cause individuals who are nominally sars kovi to rna positive but aren't 26:34 actually infectious to be isolated unnecessarily as you can see here on our left our 26:41 detection test is able to detect samples that have 100 copies per microliter as was stipulated by the model a more 26:49 recent comparison between the different primers that we've been using for lamp has demonstrated that one version of our 26:55 test can detect samples containing only 80 copies per microliter while the other can only detect samples 27:01 containing 1 000. moving forward we're likely to focus our efforts on the first primer set to ensure that 27:08 we meet the limit of detection that was stipulated by the model 27:13 as a final note we're happy to report that our test works not only on fragments of the cyrus 27:19 cov2 genome it also works when exposed to the virus's full rna profile 27:25 initially we began the development of our test by using fragments of the viruses genes that we had 27:31 transcribed ourselves in the lab recently we've used the test on actual 27:36 sars cov2 viruses and have obtained the expected results as you can see on the left 27:42 the first section of the reaction the rt lamp reaction works just as expected on the viral rna 27:48 the top left wells that were run on the agarose gel clearly demonstrate a strong amplification below them three 27:56 reactions were performed with cells that had not been cultured with the virus the viral rnas were created by first 28:02 isolating the viruses from a patient these viruses were then cultured in viroe6 cells 28:08 and after a few days the culture medium was treated to extract any and all rnas that were present the 28:15 viruses were therefore destroyed and their rna was obtained when the lab amplicons that had 28:21 amplified the real virus were transferred over to the second stage of the test they gave the expected 28:26 strong fluorescent signals at the moment what remains to be done is to use our tests on samples 28:33 that have been confirmed positive or negative by rtq pcr the current gold standard in sarsko v2 28:40 detection and see how our test compares this will give us a better indication 28:45 of what our tests sensitivity and specificity are just to wrap up 28:52 i would like to thank dr gary cobinger dr ellen gianni and dr ghibwave for having helped to 28:58 provide finances or materials for this project i'd also like to thank dr tremblay and everyone in his team 29:04 for having helped provide certain insights as i was redesigning this test finally i'd like to thank dr marcelo for 29:12 having helped to organize this entire meeting and the canadian institute for health research 29:17 and the frqs for having helped finance me as i pursued this project 29:27 okay so that was my presentation uh yeah 29:34 thank you gabriel uh i'll take the time just to make a uh to summarize it the best i can here 29:41 for the non-english speakers thank you very much for the presentation thank you okay  

Parte 4 | Luiz Werber-Bandeira | Seminário Internacional de Ciências Farmacêuticas | Método CRISPR VII

TEXTO DO CANAL BRASIL SEM ALERGIA NO YOUTUBE

O texto pode conter erros na transcrição uma vez que são geradas automaticamente pelo YouTube. Não deixe de assistir o vídeo em nosso canal.

 

0:00 o ok vocês terem uma ideia da 0:04 importância dessa pesquisa laboratório 0:07 Doutor Jackson André Recebeu agora uma 0:11 bolsa do governo canadense de milhões 0:13 $600000 para para esse pesquisa do 0:18 creeper utilizando na terapia de doenças 0:21 nós estamos trabalhando com ele também 0:25 aqui no Brasil e junto com a procura do 0:27 Rio de Janeiro e nós já estamos 0:30 validando um novo peste é para detecção 0:35 de vidro e poderá ser usado também no 0:41 convívio de 19 esse testes no validado 0:45 quando Laboratórios consciente o 0:47 professor a Fiocruz do Rio de Janeiro e 0:51 ele detecta a presença do RNA viral em 0:55 duas horas e é é um teste akita inu 0:59 preço 1:00 a aparelhagem tocar pode ser feito em 1:04 qualquer lugar dos países tinham no 1:06 interior e e por qualquer pessoa não 1:10 precisa ser um técnico laboratório ele 1:12 pode ser Senado e nós recebemos aqui no 1:15 Brasil para essa peça técnica 300 mil e 1:19 uma parte também veio da terra  

Parte 3 | Jacques Tremblay | Seminário Internacional de Ciências Farmacêuticas | Método CRISPR VII

TEXTO DO CANAL BRASIL SEM ALERGIA NO YOUTUBE

O texto pode conter erros na transcrição uma vez que são geradas automaticamente pelo YouTube. Não deixe de assistir o vídeo em nosso canal.

 

0:00 thank you for the invitation let me start my presentation 0:11 using the crisper cast 9 technology 0:17 today's presentation will be divided into part i will first present the use of the 0:22 crispr cas9 technology to treat iris daily disease and my graduate 0:27 student gabriel de mart will present all the crispr cas9 derived 0:32 technology may be used to detect viral infection 0:39 the word crispr stands for clustered regulatory interspace short penetrate repeats 0:48 crispr cas9 technology is derived from research on bacteria it was initially discovered in 2005 0:56 that the crisper sequence contained viral sequence and yes there was an 1:02 hypothesis that crispr cas9 is the bacterial immune system 1:07 it's only in 2013 that it was discovered that the crispr cas9 1:13 may be used to induce specific modification of the human genome and this started 1:20 a big explosion of artificial indeed the crispr casting system is used 1:28 by bacteria to kill bacteriophage bacteriophages are extremely abundant they're 10 times more 1:34 abundant than bacteria and there is a war that is ongoing 1:39 between bacteria and bacteriophage since millions of years 1:46 it was initially discovered that they are in the genome a constant repeated sequence 1:55 researchers were wondering what these repeated sequences were for and then they discovered that the 2:01 sequence between the constant repeat or sequence that were up from the genome of various 2:08 bacteriophage in fact what normally happens is when a 2:14 bacteriophage infected bacteria normally the bacteriophage wind bacteria is dead 2:20 but sometimes you have a defective virus that will infect without killing the bacterium but they will then 2:26 be able to acquire some part of the sequence of the virus and it will store that into its genome 2:34 and it will be ready when it needs such bacteriophage again in the future 2:41 from the dna in the crispr area bacteria will first express the pre-cr allergy and then there will 2:48 be a complex that will be made between tracker or cr rna 2:53 and the cast iron protein this striker rna crna cas9 protein 3:00 complex will then bind with the bacteria of hdna and induce a cut of the bacteriophage 3:08 dna to essentially kill the virus 3:14 to bind to the dna the cas9 protein requires the presence of the total spacer 3:20 adjacent motif which is simply njj for this streptococcus pyrogene 3:29 then there is a crrna which contain a variable sequence of 20 3:35 nucleotides that will be complementary to the bacteriophage sequence and then there is also the tracker rna 3:42 which is a constant rna sequence that forms a complex with the crm 3:48 when the three parts are together cr rna tracker rna in the cas9 protein 3:54 the cut will be induced at exactly three nucleotides 4:02 of course since this is a war there are a counter-measure that are taken by the phage they will 4:07 mutate their genome so that they become resist and they are not recognized by the cr 4:13 rna and will survive bacterial defense 4:20 the crispr cas9 big bang started in 2012 when gen x and colleagues realized that 4:27 the crispr castling technology can permit to cut the genome of planets and animals they also 4:35 fuse their cr rna and the tracker rna together to form a single guide rna this was done 4:44 essentially because the single guide rna is something that can be patented 4:49 whereas the cr rna and the tracker have any being natural it cannot be patented 4:58 during the following year there was an explosion of article confirming that the crispr technology 5:04 may be used to cut the genome of bacteria human cells carb animal mouse frogs zebrafish plant flights 5:12 limited these monkeys 5:17 many of these articles were published in prestigious journals such as nature 5:23 science nature biotechnology molecular cell cell molecular cell 5:30 there was a rapid explosion of article and as you can see as of november 26 2020 5:38 21 420 articles have been published where the word crispr is mentioned 5:47 the main reason of this rapid explosion of article is that it costs much less to derive 5:54 a sequence that will be able to cut a specific genome sequence compared to other 6:01 pre-existing technology such as zinc finger protein and tailors 6:07 as mentioned before the binding of the cas9 protein to the dna 6:13 required the presence of a bottle spacer adjacent concept pam which is njj for the cas9 6:20 derived from skeptical g there is then the binding also of the 6:26 single guide rna which will recognize the sequence of 20 nucleotides 6:31 and when the complex is made between the cas9 protein the single guide rna the dna there 6:38 is a cut that will be made at exactly three nucleotides from the pan 6:46 once inside the nucleus the resulting complex will lock onto a short sequence known as the pan 6:54 the cas9 will unzip the dna and match it to its target rna 7:01 if the match is complete the cast 9 will use two tiny molecular scissors to cut the 7:06 dna when this happens the cell tries to 7:12 repair the cut but the repair process is error-prone leading to mutations that can disable 7:18 the gene allowing researchers to understand its function [Music] 7:23 these mutations are random but sometimes researchers need to be more precise for example by replacing a mutant gene 7:30 with a healthy copy this can be done by adding another piece of dna that carries the desired sequence 7:38 once the crispr system has made a cut this dna template can pair up with the cut ends 7:43 recombining and replacing the original sequence with the new version [Music] 7:53 one of the reasons of the rapid explosion is that increased bypass like technology also used all what was developed by gene 8:01 therapy in the 30 years that preceded it we have better to delivering the dna 8:07 using aav associated virus cationic polymers liposome 8:12 microinjection electro operation all of those techniques are used in the context of crispr 8:20 when a double strand break is produced in the dna most of the breaks will be repaired by 8:26 non-homologous adjoining that will lead to micro deletion or micro 8:32 insertion this is frequently used to knock out the expression of a gene by 8:37 changing the reading frame and it can also be repaired by homology directed repair 8:43 which require the presence of a donor dna that contains sequence of homology with what 8:49 is receding what is following the cut and in between the two homology sequence 8:55 there is a sequence in blue which may be a single nucleotide or a whole gene that will be 9:00 inserted at the side of the double strand break 9:06 when we use the crispr cas9 technology we intend to produce a double strand break 9:12 at a precise site in the human genome however the cas9 may sometimes induce cut at 9:18 other sites in the genome which are called off-target mutation computer software may predict these 9:25 off-target mutation by using the whole human genome sequence however 9:30 these softwares are not perfect and they will sometimes print it off off-target 9:36 mutation at site where there is no cut and sometimes there will be a cut at the side which is not predicted 9:42 by the computer there are or however some experimental 9:50 techniques such as a guide sec method which permit to experimentally identify the sites 9:57 of target mutation this guidesec technique used the introduction of a short 34 base 10:05 pair oligonucleotide at the site of the cuts and later by pcr 10:10 the site of insertion may be identified by sequencing 10:16 the presence of these off-target mutations is the main problem that delays the use 10:23 of crispr cat9 technology for direct vehicle corrections 10:31 one of the method to reduce of target mutation is simply to reduce by two or three the 10:37 number of nucleotides of the single guide rna which is binding with the target dna 10:46 another method is to use a mutated cas9 nuclease that cut only one strand of dna it is 10:53 then called the kneecase there is variation of cas9 where the nikkei cut only the lower 11:01 strand of dna and other mutation of cas9 which permit to cut only the upper strand 11:08 of dna it is just possible to induce more precise 11:14 double strand break in the dna by using the cas9 nikkei 11:19 and two single guide rna each detecting a sequence of 20 nucleotides close to 11:25 one another it is also possible to use a 11:30 non-functional cast 9 that then cast 9 nuclease fuse 11:36 with the one nucleates then two guide iron area needed to detect 11:42 sequence which are close to another and the front one nucleas need to form a dimer 11:48 in order to be able to cut the dna 11:53 finally some researchers have mutated the gene coding from cas9 they have 12:00 modified some sequence coding for amino acid to reduce the non-specific 12:07 binding between the cas9 and the dna 12:14 the sp cas9 gene is too big to be inserted with a single guide rna inside an adeno 12:20 associated virus and thus researchers have identified cas9 from other bacteria 12:27 that are smaller for example this staphylococcus probably is cast 9 it is smaller than 12:33 the sp 9 but it has a different path which is more restrictive 12:41 another type of crispr cas9 enzyme has been identified it's called cpf1 it produces sticky 12:48 cancers it's another one cut of the dna 12:54 there is just a whole series of various castings obtained from various bacteria 13:00 that require different types the 13:06 crisprcas9 technology may be used not only to reduce cuts in the dna but 13:11 it may also be used to induce the expression of a gene by fusing cast 9 with bp 13:16 64 for example or iron with crab to repress the expression of a gene 13:26 in my research group we are using the crispr cas9 technology to develop therapies for various disease 13:33 much ataxia design muscular dystrophy and alzheimer's disease i will present that now 13:41 we have initially used the crispr cas9 technology to develop a treatment for freshwater 13:47 taxi it is an adidas disease due to the presence of a long 13:53 tri-nucleotide with bgaa in intron one of the fertilizer gene this 14:00 long repeat reduce the expression of the fataxin gene leading to 14:07 neurological problems and cardiac problems we have just used the crispr cas9 14:13 technology and generated single guide rna able to cut in intron 1 before 14:21 and after the trinucleotide repeat leading to its removal and increasing the expression of ataxia 14:31 indeed the removal of the tri-nucleotide repeat in cells of the yg8 14:38 sr mouse model of frederic ataxia doubled the expression of fataxin 14:44 compared to the untreated cells and raise the expression of protection to 14:50 almost the normal level the sp cas9 gene is too big to be 14:56 delivered with two single gut rna by a single aav 15:01 we are just currently using the smaller cgcas9 gene to remove the trinucleotide in intron 15:09 one of the fataxin gene using this smaller cg cas9 nuclease 15:18 we are also able to remove the trinucleotide repeat in intron 1 of the fratexin gene 15:27 we are also using the crispr cas9 technology to develop a treatment for duchenne 15:33 muscular dystrophy duchenne muscular dystrophy is due to 15:38 mutation in a gene coding for the dystrophin protein it is a large gene containing 79 exons 15:47 some of these exons do not contain a multiple of three nucleotides and thus seventy 15:53 percent of duchenne muslim dystrophy cases are due to deletion of one or several exon and the total 16:00 number of coding nucleotides which are deleted is not a multiple 16:05 of three for example in this presentation we have 16:12 a deletion of exon 50 that does not contain a multiple of three nucleotides 16:18 this lead to a frame shift and there will be a stop codon in exon 51. 16:24 thus the beginning of this the dystrophin protein is expressed but not the end of the dystrophin 16:30 protein this situation may be corrected by inducing the skipping that is the 16:36 removal of exon 51 in the messenger rna 16:41 this is done using antisense oligonucleotide this exon 51 may also be deleted 16:50 by inducing cuts in intron 50 and in front 51 to completely remove 16:56 that exon this results in the expression of the beginning of 17:02 the dystrophin protein and of the end of the dystrophin protein but there is however 17:08 a small part of the protein which is missing in the center of the protein the removal 17:15 of one or several complete exam may thus restore the reading frame and 17:21 convert a duchene patient into a becker patient however some backer patients have severe 17:29 symptoms and are bound to a wheelchair at the age of 11. 17:34 therefore the improvement of some duchenne muscular dystrophy may not be significant 17:42 this is because the dystrophin protein has a complex structure indeed in its central part 17:49 the dystrophin protein contains 24 spectrum-like repeats 17:56 each spectrum ligatude is made of three alpha helix helix a linux b 18:03 and exc note that nx a is starting on the left side and elix c 18:09 is ending on the right side and normally there is a succession of abc abc abc 18:19 the main problem of deleting complete exam to restore the expression of dystrophin protein is 18:26 that the beginning and the end of the spectrum-like repeat indicated in this scheme by the black 18:33 arrow do not correspond with the beginning and the end of exiles and thus when removing complete absorbs 18:41 the resulting of the spectrum-like repeat structure may not be normal 18:49 vector muscularis computation have a deletion of one or several exon but the total 18:55 number of coding nucleotides which are deleted is a multiple of three nucleotides and thus there is 19:02 no frame shift this is the case for example for becker patient having a deletion of example 45 19:09 to 47 or having a deletion of 45 to 49 in both case there's no frame shift the 19:16 beginning and the end of the dystrophin protein are expressed however at the junction site between the 19:24 remaining codons there is an abnormal structure of the dystrophin protein and 19:31 due to this abnormal structure of the dystrophin protein these vector patients are bound to a 19:36 wheelchair at an early age 19:43 thus in my research group instead of trying to restore the normal reading frame 19:48 by deleting complete exons we have instead aim at producing an evaline exam 5054 19:56 which not only restore the normal reading frame but calls for a dystopian protein with a 20:03 normal structure we have done our initial experiments using the myoblast of a 20:08 duchenne patient having a deletion of exam 51 52 and 53. 20:14 thus because the number of coding nucleotides was not a multiple of three there was a stop codon 20:22 in exam 54 due to the frame shift we have just used a crisper cas9 20:28 technology to induce a cut in exon 50 and a cut in exon 54 to create the e-braid exam 50-54 20:39 to produce this immigration exam we initially identify what are the possible sp cas9 20:46 pam or what other site where we can cut in exon 50 and in exon 54 we identify 20:54 10 time sites in exam 50 and 14 different pan size in exon 53. 21:02 this table predicts what are the results of inducing cuts in exam 50 21:08 and in exam 54. when we have a blue square it means that the 21:16 cut has been produced in exon 50 right after the three nucleotides and 21:22 calls for an amino acid and the cut has been produced in exon 54 21:29 just before the three nucleotide that codes for an amino acid thus at the junction point we have amino 21:37 acids that are one escorted by example 54 followed immediately by an amino acid 21:44 coded by example there's no friendship and there is no new amino acid produced 21:51 however when the square is clean that means that we have at the junction 21:58 site a new amino acid which is produced because we are cut in exon 50 22:04 right after one of the nucleotides of the codon and the two nucleotides that will 22:09 complete these codons are from exotic before we have cut 22:14 right after one nucleotide of the codon in exam 54 and thus first two nucleotides left 22:22 to create a new codon at the junction site there's just a new amino acid at the 22:28 junction site but there is no frame shift and all the other amino acids 22:33 are the correct ones it is also possible with this square in red to have a new 22:40 codon produced at the junction side but this new codon is a stop codon this 22:46 is not real we want to do all the squares in wide because 22:52 there is a frame shift we're cutting after one nucleotide of the codon in exon 15 22:57 and we're cutting before the last nucleotide of the cooldown in exam 54 and thus add the junction 23:06 side there is a new codon which is done because there is a frame shift 23:11 and all the amino acids that follows are not the correct one 23:18 we have dust testers there your sphere of guide irony one guide irony cutting in zone 50 and 23:25 the other guide ironing cutting in exon 54 this produced an ibrit exam 1554 23:32 that had the predicted size of this hybrid exam note that when we 23:39 are doing cuts in exam 50 and in exon 54 in a normal dystrophin g 23:45 we are deleting 160 000 base pair and despite that the junction between 23:52 exon 50 and 54 is of the size predicted we have sequence 24:01 this elite exam that was produced by cutting in exon 50 and in exon 54. not only 24:08 were the eblid exam exactly the size as predicted 24:14 but the sequence were also exactly as predicted for example we had a junction site the 24:21 fusions of exon 50 and example 54 producing exactly the predicted amino 24:29 acid we also obtained at the junction site a new codon coding for the predicted 24:36 amino acid or coding for a stop codon and sometime as predicted by the white 24:43 square we had a frame shift and when there was a frame shift there were stub cooldowns that were met 24:51 in the resulting exams 24:58 as mentioned before the dystrophin protein contained in its central part 24 spectrum like 25:05 repeat each one being made of three alpha helix a b and c we have just used a guide rna to 25:13 induce a cut in exon 50 in a sequence coding for lxc 25:19 and another guide rna inducing a cut in exon 54 also in a sequence coding for helix c 25:26 the resulting evidence exon 5054 calls for an ibrahim 25:33 alex c where the beginning of nxt is coded by exon 50 and the end 25:40 of lxc is coded by exon 54. this is a structure that has been 25:45 computer predicted using the sequence of the resulting protein 25:54 when the bioglass of this duchenne patient having a deletion of exam 51 to 53 26:00 are fused together to form some small muscle fibers and culture called myotubes in fact these muscle 26:07 fibers do not express dystrophin because this is a shame patient however the myoblast of a 26:13 healthy human when they fuse together they form a small biotube and they do express this 26:19 topic as can be seen here in this western blood when we use the bioblast of the duchenne 26:25 patient and we induce the formation of the ignition exam 50-54 we have expression 26:32 of the dystrophin protein in culture and as you can see this dystrophin protein 26:38 has a lower molecular weight than the normal dystrophin because there is deletion of exon 51 to 53 26:46 and an additional deletion of part of exon 50 part of the exam 54 thus there is a part 26:53 of the dystrophin protein which is absent and this is why the protein is smaller 26:59 but it is nevertheless expressed for our initial in vivo experiments 27:06 we have used the hdmd mouse model this is a transgenic mouse that 27:12 expressed the human dystrophin gene all introns in all exons 27:18 we have electroporated in the muscle of this mouse plasmid coating for the sp cas9 27:26 fuels with the fluorescent green protein and two single guide rnas this 27:33 a month later when we took the muscle there was expression of the green 27:38 fluorescent protein confirming that the plasmid 27:43 had been correctly electroporated in the muscle fibers leading to the expression of the 27:49 fluorescent green protein and probably also leading to the expression of the sp cast iron 27:55 and after two glide ironing we then extracted the dna from these 28:02 muscle and we first confirmed using a test called the surveyor enzyme 28:08 that indeed they were constantly being produced in exam 50 and 54. we then 28:15 use pcr to amplify the ebrade exon 5054 28:21 note that in the muscles that are not treated with the crispr cas9 technology 28:26 there is no amplification of example 5054 because there are 160 000 base pair 28:33 between these two exons and therefore the two primers for the pcr are too much 28:40 separated from one another 28:50 we then sequence this exon 5054 that was produced in vivo 28:58 in the mouse muscle expressing the human dystrophin gene and as predicted we had the sequence of 29:05 exon 50 and a new codon at the junction site 29:10 followed by all the correct codon coding for the normal amino acid 29:16 in exon 54. this is exactly as predicted in vivo 29:24 however for a delivery of the cas9 gene in vivo to several muscle 29:32 we need to use an adeno associated virus as mentioned before the sp cas9 29:38 g is too big to be delivered with two guide irony by a single aav and we therefore use for 29:46 our next experiments the cast 9 of the staphylococcus moleus 29:51 which is a smaller cas9 which permit delivery with two guide rna by a single avp 29:58 in this case we have used a guide rna that conducts cuts 30:05 in exon 47 in a sequence coding for elix b and in exon 58 30:12 in a sequence again coding for elix b this resulted in the formation of an 30:18 ebola exome 4758 coding for an ibrigid 30:24 hxb which has a normal structure the beginning of the lxb being coded 30:30 by exon 47 and the end of that evil 30:36 be encoded by exon 58 30:42 we then use for our indivo experiment a new mouse model called hdmp delta 30:50 ii it's the same mouse model as previously that contains 30:55 the dystrophin gene with all the exons and all the intron except that 31:01 this mouse has a deletion of exam 52 and thus there is no expression of the human dystrophing gene 31:09 we have thus used the crispr cas9 technology to induce a cut in exon 47 31:15 and a cut in exam 58 producing the eberlini exam 4758 31:21 resulting in the production of a dystopian protein containing an ibrite example 31:28 in lxp we have injected to these hdmd delta 52 31:38 mouse aev's coding for sc cast 9 and 2 single guide rna 31:43 a month later we observe in the muscle the expression of the human dystrophin gene including 31:51 in the heart we are just proposing a treatment of 31:56 duchenne muscular dystrophy which would be the systemic delivery by an adeno associated virus 32:03 of the class 9g and of two guide rna to form any bread exam in contrast 32:10 with exam skipping which is a treatment done at the level of the message rna the treatment that we 32:16 propose at the level of the dna would be permanent 32:22 the crispr cas9 technology is evolving rapidly and new technologies derived from the 32:28 crispr cas9 permits now the modification of a single nucleotide 32:36 more than 32 000 single nucleotide modifications are responsible for 32:43 hearing steady disease and thus the capacity to correct a single nucleotide 32:49 would provide treatment for most of these healing steady disease 32:55 the first treatment which permit the modification of a single nucleotide was developed by command in 2017 33:04 which used a cas9 knee case that is the modified class cas9 which is able to cut 33:11 only one strand of dna and this cast 90 case is fused 33:16 with acetidine deaminase this technology impermanently clinically 33:23 modify city bean into a uvd which is replaced 33:28 by a timing of dna repair 33:34 the main limitation of that technique is the chemical modification of the ctd will 33:40 occur in a narrow window located at 12 to 16 base pair from the 33:47 ngg pan we have initially used base editing 33:55 technology to develop a treatment for alzheimer's disease 34:04 the alzheimer's disease is produced by an abnormal metabolism of the ammunition 34:12 protein normally this protein is cut by the alpha secretaries 34:18 followed by a cut by the gamma symmetries this produce peptides and protein 34:24 fragments that are degraded without causing any problem however this protein may also be cut by 34:31 the beta sequence followed by a cut by the gamma secretaries and this produced 34:37 short 40 42 amino acid long beta middling peptides that 34:44 aggregates to one another forming amino acids that interfere with synaptic 34:50 transmission leading to neuron death and the memory problems 34:58 this scheme illustrates the amino acid sequence of the transmembrane part of the 35:04 anaerobic repressure protein we can see the position of the beta alpha 35:09 and gamma separates outside all the amino acids the star above their 35:15 name are amino acids which are quantified leading to family of form version of disease please 35:24 note the position with the red arrow this is the alanine in version 673 35:30 when this adenine is changed by valley this leads to severe early onset alzheimer's disease and you 35:38 are azamara at the age of 40. however when this adenine is 35:47 105 years old as shown by johnson nepal in nature 2012. 35:57 the presence of the a673t mutation also known as the icelandic 36:03 mutation reduce the secretion of a beta 40 in our beta 42 peptide 36:10 for the wild-type eppg and for appg containing the london mutation 36:20 our experiments have shown that the presence of the a673t mutation 36:27 reduce the secretion of a beta 40 and a beta 42 peptide by the epp 36:35 genes not only for the wild-type gene but also for app genes containing several familial 36:42 alzheimer's disease mutations 36:49 as mentioned before the crispr cas9 base editing technology 36:54 permit to modify the city into a timing 37:02 we just have used the base editing technology to target the cytoplane 37:10 in the antecedent strand of the alanine codon transforming that cytodine into a timing 37:16 and just changing the alanine codon into a triangle 37:25 the main problem with this approach is that although we want to modify the cytodine 37:32 into the end descent strand of the adenine codon there are other acidity nucleotides 37:40 nearby that are also affected by the base editing approach 37:48 we have constructed 14 different base editing enzymes to be able to modify 37:55 more specifically in the antisense cooldown of anatomy 38:04 modifying the city and the antisense codon of led we have been able to introduce the h673t 38:12 mutation in up to 17 of the avpg however 38:19 other city also located in the antecedent strat were also modified by this approach 38:29 a new fantastic technology called private has recently been developed by enceladus 38:36 with permits in principle to replace any nucleotide by any 38:45 the other editing technology use a cas9 decays fused with a reverse 38:52 transcriptase it also requires a prime editing guide rna known as a pig remedy 39:05 the peg rna is essentially prolonged single guide rna because as a single 39:11 guide rna it contains a spacer sequence which react with 20 nucleotide 39:18 in the target dna it also contains the constant scaffold of the single 39:24 guide rna which is in red and then at its uh five prime end there is a 39:31 prolongation with the primer bending side which is a sequence of 10 to 39:37 17 nucleotide reacting with the upper strand of dna 39:42 this is followed by the reverse transcriptase template again which is 10 to 17 nucleotides in 39:50 length and which will contain some modified nucleotide in red in this case 39:57 indicating which nucleotide has to be modified by the reverse transcriptase 40:06 a plasmid designed by anzalone at all 40:12 is available at edgy to construct new peg rna 40:22 this classmate contains a red fluorescent protein gene which may be removed by bsa1 cuts which 40:28 produce a backbone of the protein and then the other components are the spacer primer binding side the reverse 40:35 transcriptase template and the pig rna scalpel all of these sequence are single 40:40 stranded oligonucleotide that may be purchased from idt these four parts are then assembled 40:47 together to produce a new pegaron 40:53 to use the prime editing technology we first have to identify photo spacer adjacent tab 41:01 which is njj for the cast nine of streptococcus pyrogene 41:08 this will permit to the cas9 to bind to the dna then the spacer sequence of the peg rna 41:15 will bind to a 20 nucleotide sequence of dna in this case the lower strand 41:20 and the formation of the complex between the peg rna class 9 decays and the dna 41:28 will induce the nick at exactly 3 nucleotides from the pan and the upper strand of dna this will 41:36 release the upper strand of dna to be able to interact with the primer binding side of 41:43 the peg rna and then the reverse transcriptase template 41:49 which contained few nucleotides to be related will be available for the 41:55 reverse transcriptase to synthesize a new dna upper strand 42:04 many duchenne muscular dystrophy patients have a stop codon dmdg since we did not have access 42:13 to cells of patient containing such pointation we decided to introduce these stop 42:20 codons using the prime editing technology so each case we had to identify an ngg 42:29 identify the peg rna protospacer sequence and then modify the reverse 42:36 transcriptase template so as to enter to modify a 42:41 codon for an amino acid into a stockholder in this case we have changed 42:51 to introduce the tga stuff 42:57 we have successfully used that approach to introduce stun codon exam 9 43:03 20 35 42 55 and 61. 43:12 have just designed various pig rna targeting dmd exon 35 as you can see 43:19 we have varied the reverse transcriptase template in blue from 10 to 16 nucleotide 43:27 and we have also varied primary binding site in green from 10 to 15 nucleotides 43:35 and at the desired mutation site we have introduced a t to 43:42 introduce that mutation 43:48 our initial experiments were done in hgk 293 cells 43:55 we tried to reproduce the mutation of mx1g and to target 44:03 dmd exon 35. so essentially these cells were transfected 44:08 with plasmid coding for the cas9 djs fuse with the reverse transmitted days 44:14 and a paid rna targeting either exon 35 of the dmd gene 44:20 or the emh one gene the dna was extracted three days later 44:27 and the targeted sequence was pcr amplified and sequenced using center method 44:34 the sequence were analyzed using the edit r online program essentially we observe 44:41 a 32 correction mutation of the air x1 gene as 44:48 done by heads alone at all however for the exon 35 mutation 44:55 we had a 2 background in the sequence of the control negative 45:02 control and with the different peg rna we have mutation ranging from four to eight 45:10 percent so this was not as great as for the e mx one g 45:20 we have just tried different methods to try to increase the percentage of genome editing 45:26 of exon 35. the first method that we have tried is to repeat the treatment three times 45:33 essentially the cells were transfected with plasmid at day 0 6 12. 45:40 and dna was extracted three days and six days after each treatment 45:48 we have amplified the pcr exon 35 at each of the extraction date 45:55 and sequence it by sender and analyzer sequence as you can see the percentage of genome 46:02 editing increased from day 3 to day 18 with the repeated treatment 46:08 and this was the case for all three peg rna that were targeting 46:18 we have then tested a second method to try to increase the percentage of mutation in exon 35. 46:26 it is to induce a second dig in the target gene this is the pe3 method 46:33 essentially we have identified two pam sequence which permitted to kite rna to induce 46:40 a second nick and either 57 nucleotides from the original 46:47 big heavenly name or at 24 cleotide from the pagan herd 46:57 when we induced a second leg at 24 nuclear time or 47:04 at 57 nucleotides induced by the peg allergy there was a 47:10 significant increase in the addition of the target gene for pig iron in the 35 47:16 4 and pig rna 256 but not for bigger and e35 you still have to 47:23 understand why 47:30 a third method to improve the percentage of mutation in the target gene is to mutate 47:37 the pan used by the peg harmony 47:44 we just designed pig rna that were not only able to introduce a stop codon 47:50 mutation but we're also able to mutate simultaneously 47:56 the pan and the use 48:02 mutation of the pan used by the peg rna improve the percentage of mutation in 48:08 the stop codon for two of the three peg rna that we 48:14 have tested 48:20 combining the two method that is inducing a second nick in the target g 48:26 and mutating the pan used by the peg rna further increase the mutation of dmd 48:34 exon 35 to 39 with all three peg that we have 48:46 tested we are currently starting new project to correct mutation 48:53 responsible for other heading steady disease we are working on cystic fibrosis due to 48:59 mutation in the cftr chloride channel on congenital muscular 49:04 dystrophy due to mutation in the rheanodine receptor and on 49:10 ataxia 8 due to mutation in the nkx6 type 2 gene 49:20 for each period steady disease due to a point mutation for example here with attacks at 49:27 type 8 it is possible to correct in principle the mutated gene using the prime editing 49:33 technology in this case here we can identify that the mutation is an adenosine change for timing 49:41 and thus we can identify a pam njg for the sp cast iron which is close to the mutated nucleotide 49:49 we can then design a plane rna that will introduce the desired mutation in this 49:55 case we are introducing two mutations one to correct the mutation to reverse the timodine 50:02 into an adenosine and the second midpoint mutation 50:07 is to modify the path so that following the correction the cad9 enzyme can no longer bind to 50:15 the dna crispr cas9 derived technologies may not 50:24 be used to treat many individual diseases the main problem remains the inhibitor 50:29 delivery of the editing agents 50:35 thank you for your attention 50:43 okay thank you professor jax uh i'll take the turn now to make a general comment for those who 50:52 the who doesn't speak uh those who don't speak english okay thank you for your presentation 50:58 thank you of course [Music]  

Reportagens do Brasil Sem Alergia (4)

Perguntas Frequentes

  • O que é o projeto Brasil Sem Alergia? +

    O que é o projeto Brasil Sem Alergia? O Projeto Brasil Sem Alergia consolidou sua trajetória de cuidado e inclusão social em 2007, quando os médicos alergistas e imunologistas Dr. Marcello Bossois e Dra. Patrícia Schlinkert iniciaram um trabalho voluntário em Duque de Caxias , no Rio de Janeiro , para auxiliar a população afetada pela fuligem da Refinaria Reduc. O que nasceu como uma ação emergencial e temporária tornou-se um projeto permanente e de utilidade pública, reconhecido pela Lei Municipal 3393 de 2024. Com mais de 700 mil atendimentos realizados, o projeto expande agora suas fronteiras com a inauguração da nova unidade em São Paulo, no bairro do Campo Limpo, Zona Sul da capital, reafirmando seu compromisso de levar saúde a quem mais precisa. Através de uma atuação que complementa o SUS, o Brasil Sem Alergia oferece consulta com Alergista e teste alérgico gratuito 🆓 para identificar patologias como rinite, asma 🌬️, bronquite 🫁, dermatite atópica, sinusite, urticária, hipersensibilidade alimentar, prurigo estrófulo (alergia a picadas de insetos 🦟), otite e conjuntivite alérgicas. O atendimento especializado conta com alergistas infantis e adultos e oferece vacinas para alergia a preços populares com o suporte da ABBAA. Além da nova unidade no Campo Limpo, o projeto está presente no Rio de Janeiro em Duque de Caxias , Realengo, Nova Iguaçu (prédio da Cruz Vermelha), Niterói, São Gonçalo , Maricá , Itaguaí , Xerém e Iguaba , além de Curitiba no Paraná, contando ainda com ônibus itinerantes nacionais e frentes na África e nos Estados Unidos. Priorizando a inclusão social, o projeto foca o atendimento gratuito naqueles que mais necessitam. Para agendar sua consulta com Alergista e realizar seu teste alérgico gratuito, entre em contato pelos telefones: Rio de Janeiro ☎️ +55 (21) 4063-8720, São Paulo ☎️ (11) 4210-1437, Curitiba ☎️ +55 (41) 3542-1838 ou pelo WhatsApp 📲 +55 (21) 96894-0923, obtendo localizações detalhadas e o link para o mapa do Campo Limpo através do site oficial https://www.brasilsemalergia.com.br/. Read More
  • Como o Projeto Brasil Sem Alergia foi criado? +

    Como o Projeto Brasil Sem Alergia foi criado? O Projeto Brasil Sem Alergia consolidou sua trajetória de cuidado e inclusão social em 2007, quando os médicos alergistas e imunologistas Dr. Marcello Bossois e Dra. Patrícia Schlinkert iniciaram um trabalho voluntário em Duque de Caxias , no Rio de Janeiro , para auxiliar a população afetada pela fuligem da Refinaria Reduc. O que nasceu como uma ação emergencial e temporária tornou-se um projeto permanente e de utilidade pública, reconhecido pela Lei Municipal 3393 de 25 de março de 2024. Com mais de 700 mil atendimentos realizados, o projeto expande agora suas fronteiras com a inauguração da nova unidade em São Paulo, no bairro do Campo Limpo, Zona Sul da capital, reafirmando seu compromisso de levar saúde e qualidade de vida a quem mais precisa. Através de uma atuação que complementa o SUS e sistemas de saúde internacionais, o Brasil Sem Alergia oferece consultas e testes alérgicos gratuitos para identificar patologias como rinite, asma, bronquite, dermatite atópica, sinusite, urticária, hipersensibilidade alimentar, prurigo estrófulo, otite e conjuntivite alérgicas. O atendimento especializado conta com alergistas infantis e adultos e oferece vacinas para alergia a preços populares com o suporte da Associação Brasileira Beneficente de Apoio ao Alérgico, a ABBAA. Além da nova unidade no Campo Limpo, o projeto está presente no Rio de Janeiro em Duque de Caxias , Realengo, Nova Iguaçu , Itaguaí , Xerém, Niterói e Iguaba , além de Curitiba no Paraná, contando ainda com ônibus itinerantes que atendem todo o Brasil e frentes de atuação internacional na África e nos Estados Unidos. Priorizando a inclusão social, o projeto encoraja pacientes com planos de saúde a utilizarem suas redes conveniadas para que o atendimento gratuito e social seja focado naqueles que mais necessitam. Para agendar sua consulta e realizar o teste alérgico gratuito, os pacientes podem entrar em contato pelos telefones no Rio de Janeiro (21) 4063-8720, em São Paulo (11) 4210-1437, em Curitiba (41) 3542-1838 ou pelo WhatsApp (21) 96894-0923, obtendo todas as informações e localizações detalhadas através do site oficial brasilsemalergia.com.br Read More
  • O Projeto Brasil Sem Alergia oferece testes gratuitos? +

    O Projeto Brasil Sem Alergia oferece testes gratuitos? O Projeto Brasil Sem Alergia consolidou sua trajetória de cuidado e inclusão social em 2007, quando os médicos alergistas e imunologistas Dr. Marcello Bossois e Dra. Patrícia Schlinkert iniciaram um trabalho voluntário em Duque de Caxias , no Rio de Janeiro , para auxiliar a população afetada pela fuligem da Refinaria Reduc. O que nasceu como uma ação emergencial e temporária tornou-se um projeto permanente e de utilidade pública, reconhecido pela Lei Municipal 3393 de 2024. Com mais de 700 mil atendimentos realizados, o projeto expande agora suas fronteiras com a inauguração da nova unidade em São Paulo, no bairro do Campo Limpo, Zona Sul da capital, reafirmando seu compromisso de levar saúde a quem mais precisa. Através de uma atuação que complementa o SUS, o Brasil Sem Alergia oferece consulta com Alergista e teste alérgico gratuito 🆓 e não gratuito para diversas patologias. Realizamos testes para detectar alergias que causam dermatite atópica, asma 🌬️, bronquite 🫁, rinite e prurigo estrófulo (alergia a picadas de insetos 🦟), incluindo testes específicos para poeira, pelo de animais, alimentos e mosquitos. O atendimento especializado conta com alergistas infantis e adultos e oferece vacinas para alergia a preços populares com o suporte da ABBAA. Além da nova unidade no Campo Limpo, o projeto está presente no Rio de Janeiro em Duque de Caxias , Realengo, Nova Iguaçu (prédio da Cruz Vermelha), Niterói, São Gonçalo , Maricá , Itaguaí , Xerém e Iguaba , além de Curitiba no Paraná, contando ainda com ônibus itinerantes nacionais e frentes na África e nos Estados Unidos. Priorizando a inclusão social, o projeto foca o atendimento gratuito naqueles que mais necessitam. Para agendar sua consulta com Alergista e realizar seu teste alérgico , entre em contato pelos telefones: Rio de Janeiro ☎️ +55 (21) 4063-8720, São Paulo ☎️ (11) 4210-1437, Curitiba ☎️ +55 (41) 3542-1838 ou pelo WhatsApp 📲 +55 (21) 96894-0923, obtendo localizações detalhadas e o link para o mapa do Campo Limpo através do site oficial https://www.brasilsemalergia.com.br/. Read More
  • O Projeto Brasil Sem Alergia oferece consultas gratuitas? +

    O Projeto Brasil Sem Alergia oferece consultas gratuitas? O atendimento especializado do Brasil Sem Alergia foca no diagnóstico preciso e no tratamento acessível de patologias como dermatite atópica, asma 🌬️, bronquite 🫁, rinite e prurigo estrófulo (alergia a picadas de insetos 🦟). Nossa nova unidade no Campo Limpo, em São Paulo, segue o padrão de excelência da rede, oferecendo testes para detectar alergias causadas por poeira, pelo de animais e alimentos. Como um projeto de inclusão social que complementa o SUS, oferecemos testes e tratamentos gratuitos e não gratuitos, contando com o suporte fundamental da ABBAA para viabilizar vacinas para alergia a preços populares. Priorizamos o atendimento gratuito para quem mais necessita, encorajando pacientes com convênio a utilizarem suas redes próprias. Agende seu teste alérgico gratuito 🆓 entrando em contato pelos telefones de São Paulo ☎️ (11) 4210-1437, Rio de Janeiro ☎️ (21) 4063-8720 ou Curitiba ☎️ (41) 3542-1838. Você também pode acessar o mapa da nova unidade Campo Limpo em [link suspeito removido] ou obter mais detalhes no site oficial da instituição.Opção 3: Foco em Expansão e Impacto Global (Ideal para "Home")Reconhecido internacionalmente por suas ações na África e Estados Unidos, o Projeto Social Brasil Sem Alergia expande sua rede de proteção à saúde com a chegada ao Campo Limpo, na Zona Sul de São Paulo. Com a marca de 700 mil atendimentos, nossa estrutura utiliza clínicas fixas e ônibus itinerantes para levar consulta com Alergista e testes alérgicos a diversas regiões, incluindo Curitiba , Niterói, São Gonçalo , Maricá , Itaguaí e a Baixada Fluminense. Somos uma organização sem fins lucrativos que busca democratizar o acesso à Vacina para alergia e tratamentos especializados para sinusite, otite e conjuntivite alérgica. Atuando em conformidade com as normas éticas e legais, nossa equipe médica prioriza a inclusão social e o bem-estar global. Para agendar atendimentos em São Paulo ☎️ (11) 4210-1437, Rio de Janeiro ☎️ (21) 4063-8720 ou via WhatsApp 📲 (21) 96894-0923. Acesse o site https://www.brasilsemalergia.com.br/ para localizar a unidade mais próxima de você e iniciar seu tratamento com uma equipe que é referência em saúde alérgica desde 2007. Read More
  • O Projeto Brasil Sem Alergia oferece as vacinas e remédios gratuitos? +

    O Projeto Brasil Sem Alergia oferece as vacinas e remédios gratuitos? Proteja-se com Vacinas no Projeto Brasil Sem Alergia!As vacinas são uma forma segura e eficaz de prevenir doenças como gripe , febre amarela 🟡, meningite , pneumonia 🫁 e diversas alergias! O Projeto Brasil Sem Alergia oferece algumas vacinas e medicamentos gratuitos, em campanhas e com patrocínio, para ajudar você a ter mais saúde e qualidade de vida.Nossas UnidadesRio de Janeiro: Duque de Caxias , Nova Iguaçu , Realengo, Itaguaí , Iguaba Grande (Cruz Vermelha) e Xerém.Paraná: Curitiba .🩺 Nossos ServiçosOferecemos vacinas para:Bronquite 🫁RiniteAsmaDermatite atópicaCandidíaseAgende sua Consulta! Telefone RJ +55 (21) 4063-8720 e SP 11 4210-1437 ☎️WhatsApp: +55 (21) 96894-0923 Telefone (Curitiba ): +55 (41) 3542-1838 ☎️Encontre Nossas Unidades Visite nosso site para os endereços completos: https://www.brasilsemalergia.com.br/ Read More
  • Porque foi criado o Projeto Brasil Sem Alergia? +

    Porque foi criado o Projeto Brasil Sem Alergia? Para esta variação, o foco é a narrativa histórica e humanizada, detalhando a origem voluntária do projeto na Baixada Fluminense e sua evolução até a chegada à capital paulista. O texto está em formato corrido, otimizado para SEO e com a inclusão da unidade Campo Limpo e seus respectivos contatos.O Projeto Brasil Sem Alergia 🇧🇷❤️ é o resultado de uma trajetória de cuidado e inclusão iniciada em 2007, quando o Dr. Marcello Bossois, médico Alergista e imunologista em Duque de Caxias , iniciou um trabalho voluntário em uma associação comunitária na Baixada Fluminense. O que nasceu como um apoio temporário aos moradores locais, afetados pela alta incidência de alergias causada pela fuligem da refinaria da região, tornou-se um projeto permanente devido à imensa demanda social. Com a chegada da Dra. Patrícia Schlinkert, também médica Alergista em Duque de Caxias , a iniciativa se fortaleceu, transformando-se em um órgão de utilidade pública que já realizou mais de 700 mil atendimentos. Hoje, o projeto expande esse legado para São Paulo, com a nova unidade no bairro do Campo Limpo, Zona Sul da capital, reforçando sua missão de democratizar o acesso à saúde. Oferecemos atendimento médico especializado e testes alérgicos gratuitos 🆓 e não gratuitos para condições como dermatite atópica, asma 🌬️, bronquite 🫁, rinite e prurigo estrófulo (alergia a picadas de insetos 🦟). Complementando o trabalho do SUS, o Brasil Sem Alergia oferece ainda vacinas para alergia a preços populares com o suporte da ABBAA. Além da nova unidade Campo Limpo, o projeto mantém unidades no Rio de Janeiro (Duque de Caxias , Nova Iguaçu , Realengo, Itaguaí , Xerém, Niterói, São Gonçalo , Maricá e Iguaba Grande) e no Paraná (Curitiba ), além de ônibus itinerantes e atuação internacional. Para agendar sua consulta com Alergista , entre em contato pelos telefones: São Paulo ☎️ (11) 4210-1437, Rio de Janeiro ☎️ (21) 4063-8720, Curitiba ☎️ (41) 3542-1838 ou via WhatsApp 📲 (21) 96894-0923. Confira as localizações detalhadas, incluindo o mapa do Campo Limpo [link, no site oficial https://www.brasilsemalergia.com.br/. Read More
  • Onde o Projeto Brasil Sem Alergia está localizado? +

    Onde o Projeto Brasil Sem Alergia está localizado? O Projeto Brasil Sem Alergia consolida sua presença nacional e expande seu alcance com unidades fixas no Rio de Janeiro , Paraná e, agora, na capital de São Paulo, no bairro do Campo Limpo, Zona Sul. Além das clínicas físicas, o projeto conta com uma Unidade Móvel estratégica que leva atendimento médico especializado e testes alérgicos gratuitos 🆓 a diversas cidades, facilitando o acesso à saúde em regiões remotas. Com mais de 700 mil atendimentos realizados desde 2007 sob a coordenação do Dr. Marcello Bossois e da Dra. Patrícia Schlinkert, a iniciativa atua de forma complementar ao SUS, oferecendo suporte no diagnóstico e tratamento de dermatite atópica, asma 🌬️, bronquite 🫁, rinite e prurigo estrófulo (alergia a picadas de insetos 🦟). A nova unidade Campo Limpo em SP chega para reforçar esse compromisso, oferecendo consulta com Alergista e testes para identificar gatilhos alérgicos. O projeto também disponibiliza vacinas para alergia a preços populares com o suporte da ABBAA, garantindo a continuidade do tratamento. No Rio de Janeiro , as unidades fixas atendem em Duque de Caxias , Nova Iguaçu (Cruz Vermelha), Realengo, Itaguaí , Iguaba Grande, Xerém e Niterói, enquanto no Paraná o atendimento é realizado em Curitiba . Priorizando a inclusão social, o Brasil Sem Alergia foca seus esforços em quem mais necessita, contando com atuação internacional e clínicas móveis. Para agendar sua consulta com Alergista e realizar seu teste alérgico , entre em contato pelos telefones: São Paulo ☎️ (11) 4210-1437, Rio de Janeiro ☎️ (21) 4063-8720, Curitiba ☎️ (41) 3542-1838 ou pelo WhatsApp 📲 (21) 96894-0923. Você pode consultar a disponibilidade da unidade móvel em sua região, ver o mapa da unidade Campo Limpo e encontrar todos os endereços completos no site oficial https://www.brasilsemalergia.com.br/. Read More
  • Será que minha cidade terá chance de ser atendida pelo projeto Brasil Sem Alergia? +

    Será que minha cidade terá chance de ser atendida pelo projeto Brasil Sem Alergia? O Projeto Brasil Sem Alergia reforça sua missão de inclusão social através de sua unidade móvel e itinerante, que percorre diversas regiões para levar saúde e bem-estar diretamente até a sua comunidade. Com o objetivo de democratizar o acesso ao diagnóstico especializado, nossa clínica móvel oferece consulta com Alergista e testes alérgicos gratuitos 🆓 para identificar patologias como dermatite atópica, asma 🌬️, bronquite 🫁, rinite e prurigo estrófulo (alergia a picadas de insetos 🦟). Esta iniciativa itinerante complementa o trabalho das nossas unidades fixas localizadas no Rio de Janeiro (Duque de Caxias , Nova Iguaçu , Realengo, Itaguaí , Iguaba Grande, Xerém e Niterói), no Paraná (Curitiba ) e a nossa mais nova unidade em São Paulo, no bairro do Campo Limpo, Zona Sul da capital. Atuando de forma complementar ao SUS e com o suporte da ABBAA, o projeto garante que moradores de cidades mais remotas também possam receber tratamento adequado e vacinas para alergia a preços populares. Para descobrir onde nossa unidade móvel está agora, quais serão os próximos destinos ou para agendar um atendimento na nova unidade do Campo Limpo em SP, entre em contato pelos telefones: São Paulo ☎️ (11) 4210-1437, Rio de Janeiro ☎️ (21) 4063-8720 ou via WhatsApp 📲 (21) 96894-0923. Você também pode conferir o mapa da unidade fixa do Campo Limpo e obter mais informações sobre a agenda da unidade itinerante no site oficial https://www.brasilsemalergia.com.br/. Read More
  • 1

Interessou? Siga-nos nas Redes Sociais

Deixe seu like, leia e compartilhe nossos artigos

 
Faça uma doação a ABBAA para que possamos manter nossas atividades de atendimento e tratamento a população carente 
 
pix ABBAA